PMID- 22321977
OWN - NLM
STAT- MEDLINE
DCOM- 20120920
LR  - 20120210
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 91
IP  - 38
DP  - 2011 Oct 18
TI  - [Influencing factors for the plasma concentration of N-terminal brain natriuretic 
      peptide precursor in patients with heart failure due to various heart diseases].
PG  - 2683-7
AB  - OBJECTIVE: To compare the plasma concentrations of N-terminal brain natriuretic 
      peptide precursor (NT-proBNP) in patients with heart failure due to various heart 
      diseases and analyze the influencing factors. METHODS: We enrolled a total of 804 
      heart failure patients due to various heart diseases, including valvular heart 
      disease (VHD), dilated cardiomyopathy (DCM), ischemic heart diseases (IHD), 
      restrictive cardiomyopathy (RCM), hypertensive heart disease (HHD), hypertrophic 
      cardiomyopathy (HCM), pulmonary heart disease (PHD) and adult congenital heart 
      disease (CHD). The plasma concentration of NT-proBNP was measured by 
      enzyme-linked immunosorbent assay (ELISA). Multiple linear regression analysis 
      was used to detect the influencing factors for the plasma concentration of 
      NT-proBNP. RESULTS: The plasma concentration of NT-proBNP had no significant 
      difference between patients with VHD, DCM, IHD, RCM, HCM, PHD, HHD and CHD. The 
      median (25 percent, 75 percent) values were 1866 (803 - 3973), 2247 (1087 - 
      3865), 2400 (1182 - 4242), 2456 (1385 - 5839), 2204 (1053 - 3186), 2285 (1155 - 
      3424), 2313 (655 - 3850) and 2768 (795 - 4371) pmol/L respectively (P > 0.05). It 
      increased with New York Heart Association (NYHA) class from II through III to IV. 
      The median (25 percent, 75 percent) values were 646 (447 - 1015), 2160 (1118 - 
      3750) and 3342 (1549 - 5455) pmol/L respectively (P < 0.01). The patients with a 
      body mass index (BMI) of >/= 25 kg/cm(2) had a lower NT-proBNP concentration than 
      those with a BMI of < 25 kg/cm(2). The median (25 percent, 75 percent) values 
      were 1468 (784 - 3177) and 2424 (1090 - 4213) pmol/L respectively (P < 0.01). 
      Patients with a serum creatinine concentration of >/= 107 micromol/L had a higher 
      NT-proBNP concentration than those < 107 micromol/L. The median (25 percent, 75 
      percent) values were 3337 (1470 - 5380) and 1644 (781 - 3375) pmol/L respectively 
      (P < 0.01). Multiple linear regression analysis demonstrated that NYHA class, 
      creatinine, BMI, hepatic damage and diastolic pressure were independently 
      associated with the plasma concentration of NT-proBNP (all P < 0.01). CONCLUSION: 
      The plasma concentration of NT-proBNP has no significant difference between heart 
      failure patients due to various heart diseases. Its level may be affected by NYHA 
      class, serum creatinine, BMI, hepatic damage and diastolic pressure.
FAU - Wei, Bing-qi
AU  - Wei BQ
AD  - Heart Failure Care Unit, Fuwai Hospital & Cardiovascular Institute, Chinese 
      Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, 
      China.
FAU - Zhang, Jian
AU  - Zhang J
FAU - Yang, Yue-jin
AU  - Yang YJ
FAU - Zhang, Yu-hui
AU  - Zhang YH
FAU - Huang, Xiao-hong
AU  - Huang XH
FAU - Yu, Li-tian
AU  - Yu LT
FAU - Zhou, Qiong
AU  - Zhou Q
FAU - Tan, Hui-qiong
AU  - Tan HQ
FAU - Yang, Yan-min
AU  - Yang YM
FAU - Wang, Guo-gan
AU  - Wang GG
FAU - Zhu, Jun
AU  - Zhu J
LA  - chi
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Heart Failure/*blood/physiopathology
MH  - Humans
MH  - Kidney Function Tests
MH  - Liver Function Tests
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Plasma/metabolism
MH  - Young Adult
EDAT- 2012/02/11 06:00
MHDA- 2012/09/21 06:00
CRDT- 2012/02/11 06:00
PHST- 2012/02/11 06:00 [entrez]
PHST- 2012/02/11 06:00 [pubmed]
PHST- 2012/09/21 06:00 [medline]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2011 Oct 18;91(38):2683-7.